|
業務類別
|
Biotechnology |
|
業務概覽
|
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitatinggenetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated fromNorth America. |
| 公司地址
| 60 Leveroni Court, Novato, CA, USA, 94949 |
| 電話號碼
| +1 415 483-8800 |
| 傳真號碼
| +1 415 483-8810 |
| 公司網頁
| https://www.ultragenyx.com |
| 員工數量
| 1371 |
| Dr. Emil D. Kakkis, M.D.,PhD |
Director, President and Chief Executive Officer |
美元 861.10K |
27/03/2026 |
| Mr. Theodore A. Huizenga |
Senior Vice President, Corporate Controller and Chief Accounting Officer |
-- |
18/02/2026 |
| Ms. Karah Parschauer, J.D. |
Chief Legal Officer and Executive Vice President, Corporate Affairs |
美元 585.34K |
27/03/2026 |
| Mr. Dennis Karl Huang |
Chief Technical Operations Officer and Executive Vice President, Gene Therapy Operations |
-- |
27/03/2026 |
| Mr. John Richard Pinion, II |
Chief Quality Officer and Executive Vice President, Translational Sciences |
-- |
27/03/2026 |
| Dr. Eric Crombez, M.D. |
Executive Vice President and Chief Medical Officer |
美元 630.23K |
27/03/2026 |
| Mr. Erik Harris |
Chief Commercial Officer and Executive Vice President |
美元 619.69K |
27/03/2026 |
| Mr. Howard Horn |
Chief Financial Officer and Executive Vice President, Corporate Strategy |
美元 604.39K |
27/03/2026 |
|
|
| Dr. Deborah L. Dunsire,M.D. |
Independent Director |
27/03/2026 |
| Mr. Matthew K. Fust |
Independent Director |
27/03/2026 |
| Dr. Emil D. Kakkis, M.D.,PhD |
Director, President and Chief Executive Officer |
27/03/2026 |
| Mr. Daniel G. Welch |
Chairman of the Board |
27/03/2026 |
| Mr. Michael A. Narachi |
Independent Director |
27/03/2026 |
| Dr. Shehnaaz Suliman, M.B.A.,M.D.,M.Phil |
Independent Director |
27/03/2026 |
| Dr. Corazon Dating Sanders, PhD |
Independent Director |
27/03/2026 |
| Dr. Amrit Ray, M.B.A.,M.D. |
Independent Director |
27/03/2026 |
|
|
|
|
